NASDAQ:AVXL Anavex Life Sciences Q2 2026 Earnings Report $2.60 -0.02 (-0.76%) Closing price 09/14/2026 04:00 PM EasternExtended Trading$2.58 -0.02 (-0.62%) As of 09/14/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Anavex Life Sciences EPS ResultsActual EPS$0.08Consensus EPS -$0.08Beat/MissBeat by +$0.16One Year Ago EPSN/AAnavex Life Sciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAnavex Life Sciences Announcement DetailsQuarterQ2 2026Date8/25/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsAnavex Life Sciences' Q4 2026 earnings is estimated for Tuesday, November 24, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Anavex Life Sciences Earnings HeadlinesPVG Asset Management Believes ISS Acknowledges Anavex’s Repeated Missteps, Failed Board Oversight, Lack of Director Stock Ownership, and AVXL Stock Price Underperformance3 hours ago | finance.yahoo.comPVG Asset Management Believes ISS Acknowledges Anavex's Repeated Missteps, Failed Board Oversight, Lack of Director Stock Ownership, and AVXL Stock Price UnderperformanceSeptember 14 at 7:30 PM | globenewswire.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex’s Highly Qualified Director NomineesSeptember 14 at 8:56 AM | markets.businessinsider.comLeading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex's Highly Qualified Director NomineesSeptember 14 at 8:30 AM | globenewswire.comBrokerages Set Anavex Life Sciences Corp. (NASDAQ:AVXL) Target Price at $21.33September 11, 2026 | americanbankingnews.comSee More Anavex Life Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Anavex Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anavex Life Sciences and other key companies, straight to your email. Email Address About Anavex Life SciencesAnavex Life Sciences (NASDAQ:AVXL) (NASDAQ: AVXL) is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative and neurodevelopmental disorders. The company’s research centers on small-molecule treatments intended to address disease mechanisms associated with conditions affecting the central nervous system. Anavex’s lead investigational product is blarcamesine, also known as ANAVEX2-73, an orally administered compound being studied in disorders including Alzheimer’s disease, Parkinson’s disease dementia and Rett syndrome. The company has also evaluated other pipeline candidates, including ANAVEX3-71, for potential use in neurodegenerative diseases. Founded in 2004, Anavex conducts clinical development activities through research and trials involving participants in multiple geographic regions. The company is headquartered in New York and is led by Christopher U. Missling, Ph.D., who serves as president and chief executive officer.View Anavex Life Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Dividend Kings to Buy While They’re Still Beaten DownAnalysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed EarningsMarketBeat Week in Review – 09/07 - 09/11Kroger’s Textbook Entry for Buy-and-Hold InvestorsOracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in EarningsPlanet Labs Has Fallen Back to Earth, But Wall Street Still Sees a ReboundThe End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
